BPC-157 oral vs injection: which works better?

The Core Tradeoff

BPC-157 is a small peptide (15 amino acids) that is relatively stable compared to many peptides — it was originally isolated from gastric juice, after all, which is one of the most hostile biochemical environments in the body. But "relatively stable" is not the same as "fully bioavailable orally." The real question is which route matches your therapeutic goal.

Subcutaneous Injection — The Reference Route

Most preclinical and clinical experience with BPC-157 uses subcutaneous injection. Advantages:

• Predictable systemic exposure
• Bypasses gastric and intestinal degradation
• Allows localized delivery when injecting near an injury site
• Dose-response relationship is clearer

Disadvantages:

• Requires injection skill and appropriate equipment
• Injection-site reactions are the most common side effect
• Higher barrier for patients who are needle-averse

Oral BPC-157 — A Special Case

Oral administration is uncommon in standard peptide therapy, but BPC-157 is an exception because of its gastric-origin stability. Oral use makes most sense for:

• Gut-focused indications — ulcers, IBD, IBS, leaky gut, NSAID-induced damage. Direct contact with the damaged lining is a plausible advantage over systemic delivery.
• Patients who cannot or will not inject — an imperfect but real option.
• Combined protocols where oral dosing supplements injection for specifically gut-targeted benefit.

Bioavailability Reality Check

The best available data suggest oral BPC-157 bioavailability is substantially lower than subcutaneous — estimates range widely and are not precisely characterized in humans. Practical implication: if you're using oral BPC-157 for systemic effects (tendonitis, rotator cuff), you are likely under-dosing the actual target tissue. Oral is not a good substitute for injection in soft-tissue injury protocols.

Common Oral Dosing Protocol

• 250–500 mcg oral capsule or sublingual solution, 1–2 times daily
• Empty stomach — typically 15–30 minutes before meals
• For sublingual: hold under tongue 30–60 seconds before swallowing, which may improve absorption
• Cycle length similar to injection protocols (4–8 weeks)

Common Injection Dosing Protocol

• 250–500 mcg subcutaneously once or twice daily
• Insulin-gauge needle (29–31G), 5/16 to 1/2 inch
• Injection sites rotated daily between abdomen, thigh, and near injury site when applicable
• Cycle length 4–8 weeks typical

Combined Protocols

For patients with both gut issues and soft-tissue injuries, combined protocols are common:

• Subcutaneous injection 250 mcg daily for systemic/tissue effects
• Plus oral 250 mcg daily for direct gut contact

Form and Stability Considerations

• Injection: Reconstituted with bacteriostatic water, refrigerated, used within 14–30 days depending on the compounding pharmacy's stability guidance.
• Oral capsules: Refrigeration usually recommended. Shelf life typically 3–6 months from compounding.
• Sublingual solutions: Refrigerated. Shorter shelf life — often 2–4 weeks once reconstituted.

Which Should You Use?

Simple decision framework:

• Tendonitis, rotator cuff, muscle strain, ligament injury, joint pain: injection.
• IBS, mild IBD, gastric ulcer, NSAID damage, leaky gut: oral (or combined).
• Post-surgical recovery: injection, with surgical team approval.
• Can't or won't inject: oral, with honest expectations about lower systemic effect.

See the main BPC-157 guide. Related: dosing for tendonitis, BPC-157 for leaky gut.